董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Fredrickson | 男 | Director | 51 | 38.71万美元 | 2.00 | 2026-03-03 |
| Lloyd B. Minor | 男 | Director | 68 | 35.00万美元 | 0.25 | 2026-03-03 |
| David D. Halbert | 男 | Chairman and Chief Executive Officer and Founder | 70 | 2035.06万美元 | 12500.98 | 2026-03-03 |
| Brian J. Brille | 男 | Executive Vice President and Vice Chairman | 65 | 120.00万美元 | 391.18 | 2026-03-03 |
| George H. Poste | 女 | Vice Chairman | 82 | 35.00万美元 | 56.17 | 2026-03-03 |
| Jonathan Knowles | 男 | Vice Chairman | 78 | 35.00万美元 | 29.23 | 2026-03-03 |
| Peter M. Castleman | 男 | Director | 70 | 64.73万美元 | 1043.14 | 2026-03-03 |
| Joseph E. Gilliam | 男 | Director | 50 | 40.86万美元 | 7.75 | 2026-03-03 |
| Jon S. Halbert | 男 | Director | 66 | 35.00万美元 | 136.02 | 2026-03-03 |
| Laura I. Johansen | 女 | Director | 60 | 35.90万美元 | 31.46 | 2026-03-03 |
| Danny Phillips | 男 | Director | 66 | 41.21万美元 | 10.62 | 2026-03-03 |
| Jeffrey Vacirca | 男 | Director | 57 | 35.00万美元 | 3.75 | 2026-03-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David D. Halbert | 男 | Chairman and Chief Executive Officer and Founder | 70 | 2035.06万美元 | 12500.98 | 2026-03-03 |
| Brian J. Brille | 男 | Executive Vice President and Vice Chairman | 65 | 120.00万美元 | 391.18 | 2026-03-03 |
| David Spetzler | 男 | President | 50 | 1158.32万美元 | 321.11 | 2026-03-03 |
| Luke Power | 男 | Chief Accounting Officer and Chief Financial Officer and Senior Vice President | 44 | 未披露 | 未持股 | 2026-03-03 |
| J. Russel Denton | 男 | General Counsel and Secretary and Senior Vice President | 42 | 535.46万美元 | 26.23 | 2026-03-03 |
董事简历
中英对照 | 中文 | 英文- David Fredrickson
-
David Fredrickson，自2024年8月起担任Caris Life Sciences，Inc.董事会成员。Fredrickson先生目前担任阿斯利康 PLC肿瘤业务部门执行副总裁，自2017年10月起担任该职位。此前，Fredrickson先生曾担任日本阿斯利康 K.K。总裁，美国阿斯利康专科护理副总裁。在日本期间，弗雷德里克森先生还担任欧洲制药工业和协会联合会日本副主席，并担任日本制药商协会理事。在加入阿斯利康之前，Fredrickson先生曾任职于基因泰克，这是一家生物技术公司，后来成为罗氏的子公司，曾担任多个职能和领导职务，包括在西班牙担任肿瘤业务部门经理，在美国担任战略、市场营销和销售职务。在此之前，弗雷德里克森先生曾任职于全球战略咨询公司Monitor Group，LLC（现为Monitor Deloitte Group，LLC）。Fredrickson先生拥有Georgetown大学政府学文学士学位。
David Fredrickson,has served as a member of the company's board of directors since August 2024. Mr. Fredrickson currently serves as Executive Vice-President, Oncology Business Unit of AstraZeneca PLC, a publicly traded global biopharmaceutical company, a position that he has held since October 2017. Previously, Mr. Fredrickson served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care of AstraZeneca in the United States. While in Japan, Mr. Fredrickson also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Mr. Fredrickson worked at Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche, where he served in several functions and leadership positions, including as Oncology Business Unit Manager in Spain, and in strategy, marketing, and sales roles in the United States. Prior to this, Mr. Fredrickson worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy firm. Mr. Fredrickson holds a Bachelor of Arts in Government from Georgetown University. - David Fredrickson，自2024年8月起担任Caris Life Sciences，Inc.董事会成员。Fredrickson先生目前担任阿斯利康 PLC肿瘤业务部门执行副总裁，自2017年10月起担任该职位。此前，Fredrickson先生曾担任日本阿斯利康 K.K。总裁，美国阿斯利康专科护理副总裁。在日本期间，弗雷德里克森先生还担任欧洲制药工业和协会联合会日本副主席，并担任日本制药商协会理事。在加入阿斯利康之前，Fredrickson先生曾任职于基因泰克，这是一家生物技术公司，后来成为罗氏的子公司，曾担任多个职能和领导职务，包括在西班牙担任肿瘤业务部门经理，在美国担任战略、市场营销和销售职务。在此之前，弗雷德里克森先生曾任职于全球战略咨询公司Monitor Group，LLC（现为Monitor Deloitte Group，LLC）。Fredrickson先生拥有Georgetown大学政府学文学士学位。
- David Fredrickson,has served as a member of the company's board of directors since August 2024. Mr. Fredrickson currently serves as Executive Vice-President, Oncology Business Unit of AstraZeneca PLC, a publicly traded global biopharmaceutical company, a position that he has held since October 2017. Previously, Mr. Fredrickson served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care of AstraZeneca in the United States. While in Japan, Mr. Fredrickson also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Mr. Fredrickson worked at Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche, where he served in several functions and leadership positions, including as Oncology Business Unit Manager in Spain, and in strategy, marketing, and sales roles in the United States. Prior to this, Mr. Fredrickson worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy firm. Mr. Fredrickson holds a Bachelor of Arts in Government from Georgetown University.
- Lloyd B. Minor
-
Lloyd B. Minor，自2012年起担任斯坦福大学医学院院长，自2023年起担任斯坦福大学医学事务副校长。此前，他曾担任约翰斯·霍普金斯大学教务长兼学术事务高级副校长（2009-2012年），以及约翰斯·霍普金斯大学耳鼻喉科-头颈外科系主任（2003-2009年）。他拥有布朗大学的理学学士学位和医学博士学位。
Lloyd B. Minor,has served as a member of the company's board of directors since August 2021. Dr. Minor is currently the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since 2012. In addition to being the Dean of the Stanford School of Medicine, he became the Vice President for Medical Affairs at Stanford University in August 2023 and serves on the board of directors of the Stanford Health Care hospital system. Dr. Minor has also been a professor of Otolaryngology—Head and Neck Surgery and a professor of Neurobiology and Bioengineering, by courtesy, since 2012. Prior to 2012, Dr. Minor served as the Provost and Senior Vice President for Academic Affairs at Johns Hopkins University from 2009 to 2012. Dr. Minor began his career at Johns Hopkins School of Medicine in the Department of Otolaryngology—Head and Neck Surgery as a Professor from 1993 to 2003, before serving as department's Andelot Professor and Director (Chair) from 2003 to 2009. Dr. Minor has served as a member of the board of directors of Biogen, a global pharmaceutical company, since 2024. Dr. Minor also serves on the board of a private medical insurer and as an advisor to several private healthcare companies and healthcare-focused investors. Dr. Minor holds a Bachelor of Science in Biology and a Doctor of Medicine from Brown University. In 2012, Dr. Minor was elected to the National Academy of Medicine, formerly the Institute of Medicine. - Lloyd B. Minor，自2012年起担任斯坦福大学医学院院长，自2023年起担任斯坦福大学医学事务副校长。此前，他曾担任约翰斯·霍普金斯大学教务长兼学术事务高级副校长（2009-2012年），以及约翰斯·霍普金斯大学耳鼻喉科-头颈外科系主任（2003-2009年）。他拥有布朗大学的理学学士学位和医学博士学位。
- Lloyd B. Minor,has served as a member of the company's board of directors since August 2021. Dr. Minor is currently the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since 2012. In addition to being the Dean of the Stanford School of Medicine, he became the Vice President for Medical Affairs at Stanford University in August 2023 and serves on the board of directors of the Stanford Health Care hospital system. Dr. Minor has also been a professor of Otolaryngology—Head and Neck Surgery and a professor of Neurobiology and Bioengineering, by courtesy, since 2012. Prior to 2012, Dr. Minor served as the Provost and Senior Vice President for Academic Affairs at Johns Hopkins University from 2009 to 2012. Dr. Minor began his career at Johns Hopkins School of Medicine in the Department of Otolaryngology—Head and Neck Surgery as a Professor from 1993 to 2003, before serving as department's Andelot Professor and Director (Chair) from 2003 to 2009. Dr. Minor has served as a member of the board of directors of Biogen, a global pharmaceutical company, since 2024. Dr. Minor also serves on the board of a private medical insurer and as an advisor to several private healthcare companies and healthcare-focused investors. Dr. Minor holds a Bachelor of Science in Biology and a Doctor of Medicine from Brown University. In 2012, Dr. Minor was elected to the National Academy of Medicine, formerly the Institute of Medicine.
- David D. Halbert
-
David D. Halbert，2008年创立Caris Life Sciences，Inc.，自Caris Life Sciences，Inc.成立以来一直担任Caris Life Sciences，Inc.首席执行官和Caris Life Sciences，Inc.董事会主席。哈尔伯特先生和他的家人还创建并单独支持Caris基金会，这是一个成立于2002年的非营利性私人基金会，通过帮助满足贫困人口的基本需求来帮助他们。从2005年到2011年，Halbert先生担任Caris Diagnostics的董事长兼首席执行官，Caris Diagnostics是一家总部位于德克萨斯州的专门从事胃肠道病理的病理学公司，该公司于2011年被出售给Miraca Life Sciences。在加入Caris Diagnostics之前，Halbert先生曾担任AdvancePCS Inc.（“AdvancePCS”）的董事长兼首席执行官，该公司是他于1987年创立的处方福利计划管理人。Halbert先生拥有阿比林基督教大学工商管理学士学位和阿比林基督教大学荣誉理学博士学位，以表彰他对精准医学的贡献和他的全球慈善工作。
David D. Halbert,and his family also created and solely support the Caris Foundation, a non-profit, private foundation formed in 2002 that aids impoverished people by helping to provide for their basic needs. From 2005 to 2011, Mr. Halbert served as Chairman and Chief Executive Officer of Caris Diagnostics, a Texas-based pathology company specializing in gastrointestinal pathology, which was sold to Miraca Life Sciences in 2011. Prior to Caris Diagnostics, Mr. Halbert served as Chairman and Chief Executive Officer of AdvancePCS Inc. ("AdvancePCS"), a prescription benefit plan administrator that he founded in 1987. Mr. Halbert holds a Bachelor of Business Administration from Abilene Christian University and an honorary Doctor of Science from Abilene Christian University for his contributions to precision medicine and his global philanthropic work. - David D. Halbert，2008年创立Caris Life Sciences，Inc.，自Caris Life Sciences，Inc.成立以来一直担任Caris Life Sciences，Inc.首席执行官和Caris Life Sciences，Inc.董事会主席。哈尔伯特先生和他的家人还创建并单独支持Caris基金会，这是一个成立于2002年的非营利性私人基金会，通过帮助满足贫困人口的基本需求来帮助他们。从2005年到2011年，Halbert先生担任Caris Diagnostics的董事长兼首席执行官，Caris Diagnostics是一家总部位于德克萨斯州的专门从事胃肠道病理的病理学公司，该公司于2011年被出售给Miraca Life Sciences。在加入Caris Diagnostics之前，Halbert先生曾担任AdvancePCS Inc.（“AdvancePCS”）的董事长兼首席执行官，该公司是他于1987年创立的处方福利计划管理人。Halbert先生拥有阿比林基督教大学工商管理学士学位和阿比林基督教大学荣誉理学博士学位，以表彰他对精准医学的贡献和他的全球慈善工作。
- David D. Halbert,and his family also created and solely support the Caris Foundation, a non-profit, private foundation formed in 2002 that aids impoverished people by helping to provide for their basic needs. From 2005 to 2011, Mr. Halbert served as Chairman and Chief Executive Officer of Caris Diagnostics, a Texas-based pathology company specializing in gastrointestinal pathology, which was sold to Miraca Life Sciences in 2011. Prior to Caris Diagnostics, Mr. Halbert served as Chairman and Chief Executive Officer of AdvancePCS Inc. ("AdvancePCS"), a prescription benefit plan administrator that he founded in 1987. Mr. Halbert holds a Bachelor of Business Administration from Abilene Christian University and an honorary Doctor of Science from Abilene Christian University for his contributions to precision medicine and his global philanthropic work.
- Brian J. Brille
-
Brian J. Brille，自2018年1月起担任Caris Life Sciences，Inc.副董事长兼执行副总裁，并担任Caris Life Sciences，Inc.董事会成员。布里尔先生目前担任癌症研究所董事会成员，该研究所是一家资助癌症研究的非营利组织。自2022年以来，Brille先生还担任国际生物医学Research Alliance的董事会成员，这是一个非营利组织，其使命是支持NIH牛津-剑桥学者计划。在加入Caris之前，Brille先生曾于1999年至2013年在跨国投资银行和金融服务公司美银美林（现为BoFA Securities，Inc.）担任多个与金融相关的职务，包括最近于2009年至2013年担任亚太区主席兼总裁，于2005年至2008年担任企业和投资银行业务主管，并于1999年至2004年担任医疗保健投资银行业务主管。Brille先生的职业生涯始于1987年的跨国投资银行和金融服务公司摩根士丹利 & Co. LLC（“摩根士丹利”），并创立了摩根士丹利的医疗保健服务投资银行集团。布里尔先生拥有斯坦福大学法学院法学博士学位、哈佛大学肯尼迪学院公共政策硕士学位以及伊利诺伊大学会计学学士学位。
Brian J. Brille has served as Vice Chairman and Executive Vice President and as a member of board of directors since January 2018. Mr. Brille currently serves as a member of the board of trtees at the Cancer Research Institute, a non profit organization funding cancer research. Since 2022, Mr. Brille has also served as a member of the board of directors at the International Biomedical Research Alliance, a nonprofit organization with a mission to support the NIH Oxford Cambridge Scholars Program. Prior to joining Caris, Mr. Brille served in vario finance related roles for Bank of America Merrill Lynch (now BofA Securities, Inc.), a multinational investment bank and financial services company, from 1999 to 2013, including most recently as Chairman and President of Asia Pacific from 2009 to 2013, as Head of Corporate and Investment Banking from 2005 to 2008, and as Head of Healthcare Investment Banking from 1999 to 2004. Mr. Brille began his career in 1987 at Morgan Stanley & Co. LLC ("Morgan Stanley"), a multinational investment bank and financial services company, and founded Morgan Stanley's Healthcare Services Investment Banking Group. Mr. Brille holds a Juris Doctor from Stanford Law School, a Master in Public Policy from the Harvard Kennedy School, and a Bachelor of Science in Accounting from the University of Illinois. - Brian J. Brille，自2018年1月起担任Caris Life Sciences，Inc.副董事长兼执行副总裁，并担任Caris Life Sciences，Inc.董事会成员。布里尔先生目前担任癌症研究所董事会成员，该研究所是一家资助癌症研究的非营利组织。自2022年以来，Brille先生还担任国际生物医学Research Alliance的董事会成员，这是一个非营利组织，其使命是支持NIH牛津-剑桥学者计划。在加入Caris之前，Brille先生曾于1999年至2013年在跨国投资银行和金融服务公司美银美林（现为BoFA Securities，Inc.）担任多个与金融相关的职务，包括最近于2009年至2013年担任亚太区主席兼总裁，于2005年至2008年担任企业和投资银行业务主管，并于1999年至2004年担任医疗保健投资银行业务主管。Brille先生的职业生涯始于1987年的跨国投资银行和金融服务公司摩根士丹利 & Co. LLC（“摩根士丹利”），并创立了摩根士丹利的医疗保健服务投资银行集团。布里尔先生拥有斯坦福大学法学院法学博士学位、哈佛大学肯尼迪学院公共政策硕士学位以及伊利诺伊大学会计学学士学位。
- Brian J. Brille has served as Vice Chairman and Executive Vice President and as a member of board of directors since January 2018. Mr. Brille currently serves as a member of the board of trtees at the Cancer Research Institute, a non profit organization funding cancer research. Since 2022, Mr. Brille has also served as a member of the board of directors at the International Biomedical Research Alliance, a nonprofit organization with a mission to support the NIH Oxford Cambridge Scholars Program. Prior to joining Caris, Mr. Brille served in vario finance related roles for Bank of America Merrill Lynch (now BofA Securities, Inc.), a multinational investment bank and financial services company, from 1999 to 2013, including most recently as Chairman and President of Asia Pacific from 2009 to 2013, as Head of Corporate and Investment Banking from 2005 to 2008, and as Head of Healthcare Investment Banking from 1999 to 2004. Mr. Brille began his career in 1987 at Morgan Stanley & Co. LLC ("Morgan Stanley"), a multinational investment bank and financial services company, and founded Morgan Stanley's Healthcare Services Investment Banking Group. Mr. Brille holds a Juris Doctor from Stanford Law School, a Master in Public Policy from the Harvard Kennedy School, and a Bachelor of Science in Accounting from the University of Illinois.
- George H. Poste
-
George H. Poste，自Caris Life Sciences，Inc.于2008年成立以来，一直担任Caris Life Sciences，Inc.副董事长。自2009年2月以来，Poste博士担任亚利桑那州立大学复杂自适应系统计划的首席科学家，该计划将整个大学在合成生物学、泛在传感和用于个性化医疗的医疗保健信息学研究方面的专业知识联系起来，并担任Del E. Webb健康创新教授。2003年5月至2009年2月，Poste博士担任亚利桑那州立大学生物设计研究所所长。自2000年1月起，Poste博士担任Health Technology Networks的首席执行官，该公司是一家专门从事基因组技术和计算在医疗保健中应用的咨询公司。1992年7月至1999年12月，Poste博士担任制药公司SmithKline Beecham Corporation的首席科学技术官兼研发总裁。Poste博士于2000年1月至2009年12月在美国国防部国防科学委员会任职，是两党生物防御委员会以及其他美国政府组织的成员，负责就推进针对生物武器和生物战的防御的国家安全政策提供建议。Poste博士自2004年起担任基于基因组学的药物发现公司Exelixis, Inc.的董事会成员。此前，Poste博士曾于2003年至2018年担任农业产品和解决方案提供商孟山都公司的董事会成员、DNA取证公司Orchid Cellmark，Inc.于2002年至2009年、AdvancePCS于2002年至2005年、生物技术公司Structural GenomiX于2000年至2003年、依诺米那于2000年至2003年。Poste博士还在多个科学顾问委员会任职，包括Synthetic Genomics Inc.、VirBiotech、密歇根大学陶布曼研究所和MIDAS Advanced Computing Initiative。波斯特博士是英国皇家学会、英国医学科学院、美国医学和生物工程研究所的研究员。波斯特博士也是外交关系委员会的成员，此前曾担任胡佛研究所斯坦福大学的成员，并获得了多所大学的多个荣誉博士学位。Poste博士拥有英国布里斯托大学的兽医学博士和病毒学哲学博士学位，以及英国皇家病理学家学院的病理学委员会认证。
George H. Poste,has served as the Chief Scientist of the Complex Adaptive Systems Initiative at Arizona State University, a program that links expertise across the university in research on synthetic biology, ubiquitous sensing, and healthcare informatics for personalized medicine, and as the Del E. Webb Professor of Health Innovation. From May 2003 to February 2009, Dr. Poste served as Director of The Biodesign Institute at Arizona State University. Since January 2000, Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare. From July 1992 to December 1999, Dr. Poste was the Chief Science and Technology Officer and President, R&D, of SmithKline Beecham Corporation, a pharmaceutical company. Dr. Poste served on the Defense Science Board of the U.S. Department of Defense from January 2000 to December 2009 and is a member of the Bipartisan Commission on Biodefense as well as other U.S. government organizations to advise on national security policy on advancing defenses against bioweapons and biowarfare. Dr. Poste has served as a member of the board of directors of Exelixis,Inc., a genomics-based drug discovery company, since 2004. Previously, Dr. Poste served as a member of the board of directors of Monsanto Company, a provider of agricultural products and solutions, from 2003 to 2018, Orchid Cellmark, Inc., a DNA forensics company, from 2002 to 2009, AdvancePCS, from 2002 to 2005, Structural GenomiX, a biotechnology company, from 2000 to 2003, and Illumina, from 2000 to 2003. Dr. Poste also serves on several scientific advisory boards, including Synthetic Genomics Inc., VirBiotech, the University of Michigan Taubman Institute, and MIDAS Advanced Computing Initiative. Dr. Poste is a Fellow of the UK Royal Society, the UK Academy of Medical Sciences, American Institute for Medical and Biological Engineering. Dr. Poste is also a member of the Council for Foreign Relations and previously served as a member of the Hoover Institution, Stanford University, and has received several honorary doctorates from several universities. Dr. Poste holds a Doctor of Veterinary Medicine and a Doctor of Philosophy in Virology from the University of Bristol, England and Board Certification in Pathology from the Royal College of Pathologists. - George H. Poste，自Caris Life Sciences，Inc.于2008年成立以来，一直担任Caris Life Sciences，Inc.副董事长。自2009年2月以来，Poste博士担任亚利桑那州立大学复杂自适应系统计划的首席科学家，该计划将整个大学在合成生物学、泛在传感和用于个性化医疗的医疗保健信息学研究方面的专业知识联系起来，并担任Del E. Webb健康创新教授。2003年5月至2009年2月，Poste博士担任亚利桑那州立大学生物设计研究所所长。自2000年1月起，Poste博士担任Health Technology Networks的首席执行官，该公司是一家专门从事基因组技术和计算在医疗保健中应用的咨询公司。1992年7月至1999年12月，Poste博士担任制药公司SmithKline Beecham Corporation的首席科学技术官兼研发总裁。Poste博士于2000年1月至2009年12月在美国国防部国防科学委员会任职，是两党生物防御委员会以及其他美国政府组织的成员，负责就推进针对生物武器和生物战的防御的国家安全政策提供建议。Poste博士自2004年起担任基于基因组学的药物发现公司Exelixis, Inc.的董事会成员。此前，Poste博士曾于2003年至2018年担任农业产品和解决方案提供商孟山都公司的董事会成员、DNA取证公司Orchid Cellmark，Inc.于2002年至2009年、AdvancePCS于2002年至2005年、生物技术公司Structural GenomiX于2000年至2003年、依诺米那于2000年至2003年。Poste博士还在多个科学顾问委员会任职，包括Synthetic Genomics Inc.、VirBiotech、密歇根大学陶布曼研究所和MIDAS Advanced Computing Initiative。波斯特博士是英国皇家学会、英国医学科学院、美国医学和生物工程研究所的研究员。波斯特博士也是外交关系委员会的成员，此前曾担任胡佛研究所斯坦福大学的成员，并获得了多所大学的多个荣誉博士学位。Poste博士拥有英国布里斯托大学的兽医学博士和病毒学哲学博士学位，以及英国皇家病理学家学院的病理学委员会认证。
- George H. Poste,has served as the Chief Scientist of the Complex Adaptive Systems Initiative at Arizona State University, a program that links expertise across the university in research on synthetic biology, ubiquitous sensing, and healthcare informatics for personalized medicine, and as the Del E. Webb Professor of Health Innovation. From May 2003 to February 2009, Dr. Poste served as Director of The Biodesign Institute at Arizona State University. Since January 2000, Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare. From July 1992 to December 1999, Dr. Poste was the Chief Science and Technology Officer and President, R&D, of SmithKline Beecham Corporation, a pharmaceutical company. Dr. Poste served on the Defense Science Board of the U.S. Department of Defense from January 2000 to December 2009 and is a member of the Bipartisan Commission on Biodefense as well as other U.S. government organizations to advise on national security policy on advancing defenses against bioweapons and biowarfare. Dr. Poste has served as a member of the board of directors of Exelixis,Inc., a genomics-based drug discovery company, since 2004. Previously, Dr. Poste served as a member of the board of directors of Monsanto Company, a provider of agricultural products and solutions, from 2003 to 2018, Orchid Cellmark, Inc., a DNA forensics company, from 2002 to 2009, AdvancePCS, from 2002 to 2005, Structural GenomiX, a biotechnology company, from 2000 to 2003, and Illumina, from 2000 to 2003. Dr. Poste also serves on several scientific advisory boards, including Synthetic Genomics Inc., VirBiotech, the University of Michigan Taubman Institute, and MIDAS Advanced Computing Initiative. Dr. Poste is a Fellow of the UK Royal Society, the UK Academy of Medical Sciences, American Institute for Medical and Biological Engineering. Dr. Poste is also a member of the Council for Foreign Relations and previously served as a member of the Hoover Institution, Stanford University, and has received several honorary doctorates from several universities. Dr. Poste holds a Doctor of Veterinary Medicine and a Doctor of Philosophy in Virology from the University of Bristol, England and Board Certification in Pathology from the Royal College of Pathologists.
- Jonathan Knowles
-
Jonathan Knowles，自2010年起担任Caris Life Sciences，Inc.副董事长。诺尔斯博士于1998年9月至2010年1月期间担任瑞士跨国医疗保健公司罗氏控股公司（“罗氏”）的集团研究总裁，并于1998年1月至2010年1月期间担任其公司执行委员会成员。从1998年1月到2010年1月，诺尔斯博士担任董事会成员和公司治理委员会主席，该公司是一家生物技术公司，后来成为罗氏的子公司。2007年1月至2010年1月，诺尔斯博士担任欧洲制药工业协会联合会研究主任小组主席。他还曾在多家制药公司的董事会任职。诺尔斯博士是洛桑联邦理工学院é cole Polytechnique F é d é rale de Lausanne名誉教授、芬兰赫尔辛基大学个性化医学特聘教授、牛津大学客座教授。诺尔斯博士拥有东英吉利大学分子遗传学理学学士学位和爱丁堡大学线粒体遗传学哲学博士学位。
Jonathan Knowles,served as the President of Group Research at Roche Holding AG ("Roche"), a Swiss multinational healthcare company, from September 1998 to January 2010 and as a member of its Corporate Executive Committee from January 1998 to January 2010. From January 1998 to January 2010, Dr. Knowles served as a member of the board of directors and as Chairman of the Corporate Governance Committee of Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche. From January 2007 to January 2010, Dr. Knowles served as the Chairman of the Research Directors' Group of the European Federation of Pharmaceutical Industry Associations. He has also served on the boards of directors of various pharmaceutical companies. Dr. Knowles is a Professor Emeritus at the cole Polytechnique Fédérale de Lausanne, a Distinguished Professor in Personalized Medicine at the University of Helsinki, Finland, and a visiting Professor at the University of Oxford. Dr. Knowles holds a Bachelor of Science in Molecular Genetics from the University of East Anglia and a Doctor of Philosophy in Genetics of Mitochondria from the University of Edinburgh. - Jonathan Knowles，自2010年起担任Caris Life Sciences，Inc.副董事长。诺尔斯博士于1998年9月至2010年1月期间担任瑞士跨国医疗保健公司罗氏控股公司（“罗氏”）的集团研究总裁，并于1998年1月至2010年1月期间担任其公司执行委员会成员。从1998年1月到2010年1月，诺尔斯博士担任董事会成员和公司治理委员会主席，该公司是一家生物技术公司，后来成为罗氏的子公司。2007年1月至2010年1月，诺尔斯博士担任欧洲制药工业协会联合会研究主任小组主席。他还曾在多家制药公司的董事会任职。诺尔斯博士是洛桑联邦理工学院é cole Polytechnique F é d é rale de Lausanne名誉教授、芬兰赫尔辛基大学个性化医学特聘教授、牛津大学客座教授。诺尔斯博士拥有东英吉利大学分子遗传学理学学士学位和爱丁堡大学线粒体遗传学哲学博士学位。
- Jonathan Knowles,served as the President of Group Research at Roche Holding AG ("Roche"), a Swiss multinational healthcare company, from September 1998 to January 2010 and as a member of its Corporate Executive Committee from January 1998 to January 2010. From January 1998 to January 2010, Dr. Knowles served as a member of the board of directors and as Chairman of the Corporate Governance Committee of Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche. From January 2007 to January 2010, Dr. Knowles served as the Chairman of the Research Directors' Group of the European Federation of Pharmaceutical Industry Associations. He has also served on the boards of directors of various pharmaceutical companies. Dr. Knowles is a Professor Emeritus at the cole Polytechnique Fédérale de Lausanne, a Distinguished Professor in Personalized Medicine at the University of Helsinki, Finland, and a visiting Professor at the University of Oxford. Dr. Knowles holds a Bachelor of Science in Molecular Genetics from the University of East Anglia and a Doctor of Philosophy in Genetics of Mitochondria from the University of Edinburgh.
- Peter M. Castleman
-
Peter M. Castleman，自2008年起担任公司董事会成员，自2025年起担任首席独立董事。Castleman先生是一位私人公司投资者和企业家。Castleman先生积极参与了大约十几家私营公司，通过他在2006年12月成立的家族办公室，他成为了这些公司的重要所有者。在建立家族办公室之前，Castleman先生曾于1992年12月至2006年12月担任私募股权公司J.H. Whitney & Co.，LLC的董事长兼管理合伙人，负责监督该公司的所有活动，包括私募股权投资业务。在1987年5月加入J. H. Whitney & Co.，LLC之前，Castleman先生在摩根士丹利 & Co. LLC（摩根士丹利）的杠杆收购投资小组任职。Castleman先生的职业生涯始于摩根大通证券有限责任公司（J.P. Morgan），在那里他是一名国际银行官员。Castleman先生拥有哈佛商学院的工商管理硕士学位，他曾是贝克学者，杜克大学的文学学士学位，并以优异成绩和Phi Beta Kappa毕业。
Peter M. Castleman,has served as a member of the company's board of directors since 2008 and as Lead Independent Director since 2025. Mr. Castleman is a private company investor and entrepreneur. Mr. Castleman is actively involved with about a dozen private companies where he is a significant owner through his family office, which he established in December 2006. Prior to establishing his family office, Mr. Castleman was the Chairman and Managing Partner of J. H. Whitney & Co., LLC, a private equity firm, from December 1992 to December 2006, where he oversaw all the firm's activities, including the private equity investing business. Prior to joining J. H. Whitney & Co., LLC in May 1987, Mr. Castleman was with Morgan Stanley & Co. LLC (Morgan Stanley) in their leveraged buyout investment group. Mr. Castleman started his career at J.P. Morgan Securities LLC (J.P. Morgan), where he was an international banking officer. Mr. Castleman holds a Master of Business Administration from Harvard Business School where he was a Baker Scholar and a Bachelor of Arts from Duke University where he graduated Summa Cum Laude and Phi Beta Kappa. - Peter M. Castleman，自2008年起担任公司董事会成员，自2025年起担任首席独立董事。Castleman先生是一位私人公司投资者和企业家。Castleman先生积极参与了大约十几家私营公司，通过他在2006年12月成立的家族办公室，他成为了这些公司的重要所有者。在建立家族办公室之前，Castleman先生曾于1992年12月至2006年12月担任私募股权公司J.H. Whitney & Co.，LLC的董事长兼管理合伙人，负责监督该公司的所有活动，包括私募股权投资业务。在1987年5月加入J. H. Whitney & Co.，LLC之前，Castleman先生在摩根士丹利 & Co. LLC（摩根士丹利）的杠杆收购投资小组任职。Castleman先生的职业生涯始于摩根大通证券有限责任公司（J.P. Morgan），在那里他是一名国际银行官员。Castleman先生拥有哈佛商学院的工商管理硕士学位，他曾是贝克学者，杜克大学的文学学士学位，并以优异成绩和Phi Beta Kappa毕业。
- Peter M. Castleman,has served as a member of the company's board of directors since 2008 and as Lead Independent Director since 2025. Mr. Castleman is a private company investor and entrepreneur. Mr. Castleman is actively involved with about a dozen private companies where he is a significant owner through his family office, which he established in December 2006. Prior to establishing his family office, Mr. Castleman was the Chairman and Managing Partner of J. H. Whitney & Co., LLC, a private equity firm, from December 1992 to December 2006, where he oversaw all the firm's activities, including the private equity investing business. Prior to joining J. H. Whitney & Co., LLC in May 1987, Mr. Castleman was with Morgan Stanley & Co. LLC (Morgan Stanley) in their leveraged buyout investment group. Mr. Castleman started his career at J.P. Morgan Securities LLC (J.P. Morgan), where he was an international banking officer. Mr. Castleman holds a Master of Business Administration from Harvard Business School where he was a Baker Scholar and a Bachelor of Arts from Duke University where he graduated Summa Cum Laude and Phi Beta Kappa.
- Joseph E. Gilliam
-
Joseph E. Gilliam，自2021年4月起担任公司董事会成员。Gilliam先生目前担任眼科制药和医疗器械公司Glaukos Corporation的总裁兼首席运营官，自2022年4月起担任该职位。2017年5月至2022年4月，Gilliam先生在Glaukos Corporation担任首席财务官兼企业发展高级副总裁。在加入Glaukos Corporation之前，Gilliam先生曾于2013年至2017年5月在摩根大通 & Co.担任医疗保健投资银行集团的董事总经理，在那里他领导了Glaukos Corporation的首次公开发行。从2000年到2013年，Gilliam先生在摩根大通及其前身组织Beacon Group和Chase Manhattan担任越来越重要的职务，在并购、一级和二级公开股票发行、银行借贷、债券发行和其他交易方面拥有丰富的经验。Gilliam先生的职业生涯始于普华永道会计师事务所（PricewaterhouseCoopers LLP），担任审计员。Gilliam先生拥有印第安纳大学凯利商学院会计学学士学位。
Joseph E. Gilliam,has served as a member of the company's board of directors since April 2021. Mr. Gilliam is currently the President and Chief Operating Officer at Glaukos Corporation, an ophthalmic pharmaceutical and medical device company, a position he has held since April 2022. From May 2017 to April 2022, Mr. Gilliam was Chief Financial Officer and Senior Vice President, Corporate Development at Glaukos Corporation. Prior to Glaukos Corporation, Mr. Gilliam served as a Managing Director in the Healthcare Investment Banking group at JPMorgan Chase & Co., from 2013 to May 2017, where he led the initial public offering for Glaukos Corporation. From 2000 to 2013, Mr. Gilliam held positions of increasing responsibility at JP Morgan Chase and its predecessor organizations The Beacon Group and Chase Manhattan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bnd offerings and other transactions. Mr. Gilliam started his career at PricewaterhouseCoopers LLP as an Auditor. Mr. Gilliam holds a Bachelor of Science in accounting from the Kelly School of Business at Indiana University. - Joseph E. Gilliam，自2021年4月起担任公司董事会成员。Gilliam先生目前担任眼科制药和医疗器械公司Glaukos Corporation的总裁兼首席运营官，自2022年4月起担任该职位。2017年5月至2022年4月，Gilliam先生在Glaukos Corporation担任首席财务官兼企业发展高级副总裁。在加入Glaukos Corporation之前，Gilliam先生曾于2013年至2017年5月在摩根大通 & Co.担任医疗保健投资银行集团的董事总经理，在那里他领导了Glaukos Corporation的首次公开发行。从2000年到2013年，Gilliam先生在摩根大通及其前身组织Beacon Group和Chase Manhattan担任越来越重要的职务，在并购、一级和二级公开股票发行、银行借贷、债券发行和其他交易方面拥有丰富的经验。Gilliam先生的职业生涯始于普华永道会计师事务所（PricewaterhouseCoopers LLP），担任审计员。Gilliam先生拥有印第安纳大学凯利商学院会计学学士学位。
- Joseph E. Gilliam,has served as a member of the company's board of directors since April 2021. Mr. Gilliam is currently the President and Chief Operating Officer at Glaukos Corporation, an ophthalmic pharmaceutical and medical device company, a position he has held since April 2022. From May 2017 to April 2022, Mr. Gilliam was Chief Financial Officer and Senior Vice President, Corporate Development at Glaukos Corporation. Prior to Glaukos Corporation, Mr. Gilliam served as a Managing Director in the Healthcare Investment Banking group at JPMorgan Chase & Co., from 2013 to May 2017, where he led the initial public offering for Glaukos Corporation. From 2000 to 2013, Mr. Gilliam held positions of increasing responsibility at JP Morgan Chase and its predecessor organizations The Beacon Group and Chase Manhattan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bnd offerings and other transactions. Mr. Gilliam started his career at PricewaterhouseCoopers LLP as an Auditor. Mr. Gilliam holds a Bachelor of Science in accounting from the Kelly School of Business at Indiana University.
- Jon S. Halbert
-
Jon S. Halbert，自2014年5月起担任公司董事会成员。Halbert先生目前担任Allegiance Group的董事会成员，Allegiance Group是美国领先的非营利组织筹款服务提供商，他自2023年1月以来一直担任该职位。自2007年8月以来，Halbert先生还担任Pursuant Group的董事会成员，Pursuant Group是一家专注于非营利组织的营销和筹款组织，于2023年4月与Allegiance Group合并。哈尔伯特先生目前还担任总部位于达拉斯的非营利组织Forest Forward的董事会成员，这些组织专注于贫困和南达拉斯的振兴。Halbert先生曾担任Phytel，Inc.的董事长，该公司是一家技术驱动的、由供应商主导的人口健康改善公司，直到2015年与国际商业机器公司合并。在加入Phytel，Inc.之前，Halbert先生从1987年开始与他人共同创立AdvancePCS并担任副董事长，直到2004年AdvancePCS与CVS Caremark Corporation合并。Halbert先生拥有阿比林基督教大学会计学学士学位。
Jon S. Halbert,has served as a member of the company's board of directors since May 2014. Mr. Halbert currently serves as a member of the board of directors at Allegiance Group, a leading provider of fundraising services to nonprofit organizations in the United States, a position he has held since January 2023. Since August 2007, Mr. Halbert has also served as a member of the board of directors of the Pursuant Group, a nonprofit-focused marketing and fundraising organization that merged with the Allegiance Group in April 2023. Mr. Halbert also currently serves on the board of directors of Forest Forward, Dallas-based nonprofit organizations that focus on poverty and the revitalization of South Dallas. Mr. Halbert served as the Chairman of Phytel, Inc., a technology driven provider-led population health improvement company, until its merger with the International Business Machines Corporation in 2015. Prior to Phytel, Inc., Mr. Halbert co-founded and served as Vice Chairman of AdvancePCS from 1987 until its merger with CVS Caremark Corporation in 2004. Mr. Halbert holds a Bachelor of Accounting from Abilene Christian University. - Jon S. Halbert，自2014年5月起担任公司董事会成员。Halbert先生目前担任Allegiance Group的董事会成员，Allegiance Group是美国领先的非营利组织筹款服务提供商，他自2023年1月以来一直担任该职位。自2007年8月以来，Halbert先生还担任Pursuant Group的董事会成员，Pursuant Group是一家专注于非营利组织的营销和筹款组织，于2023年4月与Allegiance Group合并。哈尔伯特先生目前还担任总部位于达拉斯的非营利组织Forest Forward的董事会成员，这些组织专注于贫困和南达拉斯的振兴。Halbert先生曾担任Phytel，Inc.的董事长，该公司是一家技术驱动的、由供应商主导的人口健康改善公司，直到2015年与国际商业机器公司合并。在加入Phytel，Inc.之前，Halbert先生从1987年开始与他人共同创立AdvancePCS并担任副董事长，直到2004年AdvancePCS与CVS Caremark Corporation合并。Halbert先生拥有阿比林基督教大学会计学学士学位。
- Jon S. Halbert,has served as a member of the company's board of directors since May 2014. Mr. Halbert currently serves as a member of the board of directors at Allegiance Group, a leading provider of fundraising services to nonprofit organizations in the United States, a position he has held since January 2023. Since August 2007, Mr. Halbert has also served as a member of the board of directors of the Pursuant Group, a nonprofit-focused marketing and fundraising organization that merged with the Allegiance Group in April 2023. Mr. Halbert also currently serves on the board of directors of Forest Forward, Dallas-based nonprofit organizations that focus on poverty and the revitalization of South Dallas. Mr. Halbert served as the Chairman of Phytel, Inc., a technology driven provider-led population health improvement company, until its merger with the International Business Machines Corporation in 2015. Prior to Phytel, Inc., Mr. Halbert co-founded and served as Vice Chairman of AdvancePCS from 1987 until its merger with CVS Caremark Corporation in 2004. Mr. Halbert holds a Bachelor of Accounting from Abilene Christian University.
- Laura I. Johansen
-
Laura I. Johansen，自2008年创立以来一直担任公司董事会成员。Johansen女士担任公司副董事长至2012年2月。2015年，约翰森女士创立了Pence Management，目前担任总裁，这是一家专注于房地产和股权投资的家族办公室。Johansen女士曾于2004年至2010年担任Halbert & Associates，LLC（“Halbert & Associates”）总裁，该公司是Halbert先生的家族办公室。Johansen女士从1996年开始担任AdvancePCS的总法律顾问，并从2001年起担任高级副总裁兼公司秘书，直到2004年该公司与CVS Caremark Corporation合并。在加入AdvancePCS之前，Johansen女士曾在国际律师事务所Akin，Gump，Strauss，Hauer和Feld LLP的企业和证券组担任协理。Johansen女士拥有得克萨斯大学市场营销工商管理学士学位和法学博士学位。
Laura I. Johansen,has served as a member of the company's board of directors since founding in 2008. Ms. Johansen served as the company's Vice Chairman until February 2012. In 2015, Ms. Johansen founded and currently serves as the President of Pence Management, a family office focused on real estate and equity investments. Ms. Johansen previously served as the President of Halbert & Associates, LLC ("Halbert & Associates"), the family office of Mr. Halbert, from 2004 to 2010. Ms. Johansen served as AdvancePCS's General Counsel beginning in 1996 and served as Senior Vice President and Corporate Secretary from 2001 until its merger with CVS Caremark Corporation in 2004. Before joining AdvancePCS, Ms. Johansen served as an Associate in the Corporate and Securities Group of Akin, Gump, Strauss, Hauer and Feld LLP, an international law firm. Ms. Johansen holds a Bachelor of Business Administration in Marketing and a Juris Doctor from the University of Texas. - Laura I. Johansen，自2008年创立以来一直担任公司董事会成员。Johansen女士担任公司副董事长至2012年2月。2015年，约翰森女士创立了Pence Management，目前担任总裁，这是一家专注于房地产和股权投资的家族办公室。Johansen女士曾于2004年至2010年担任Halbert & Associates，LLC（“Halbert & Associates”）总裁，该公司是Halbert先生的家族办公室。Johansen女士从1996年开始担任AdvancePCS的总法律顾问，并从2001年起担任高级副总裁兼公司秘书，直到2004年该公司与CVS Caremark Corporation合并。在加入AdvancePCS之前，Johansen女士曾在国际律师事务所Akin，Gump，Strauss，Hauer和Feld LLP的企业和证券组担任协理。Johansen女士拥有得克萨斯大学市场营销工商管理学士学位和法学博士学位。
- Laura I. Johansen,has served as a member of the company's board of directors since founding in 2008. Ms. Johansen served as the company's Vice Chairman until February 2012. In 2015, Ms. Johansen founded and currently serves as the President of Pence Management, a family office focused on real estate and equity investments. Ms. Johansen previously served as the President of Halbert & Associates, LLC ("Halbert & Associates"), the family office of Mr. Halbert, from 2004 to 2010. Ms. Johansen served as AdvancePCS's General Counsel beginning in 1996 and served as Senior Vice President and Corporate Secretary from 2001 until its merger with CVS Caremark Corporation in 2004. Before joining AdvancePCS, Ms. Johansen served as an Associate in the Corporate and Securities Group of Akin, Gump, Strauss, Hauer and Feld LLP, an international law firm. Ms. Johansen holds a Bachelor of Business Administration in Marketing and a Juris Doctor from the University of Texas.
- Danny Phillips
-
Danny Phillips，自2015年8月起担任公司董事会成员。菲利普斯先生目前是德克萨斯州林代尔钻石P长角牛牧场的所有者，并管理自己的金融投资。菲利普斯先生目前担任Fortress Youth Development Center的董事会成员，该中心是一家帮助德克萨斯州沃思堡无家可归者社区和低收入家庭的非营利组织，并在2007年至2015年期间担任其主席。此外，菲利普斯先生目前担任Mission Increase Fort Worth的董事会成员，这是一家非营利组织，提供教学、辅导、咨询和筹款工具，以帮助其他非营利组织成长并取得成功。此前，他还曾担任得州工人补偿提供商Texas Mutual Insurance Company的董事会成员，该职位他担任了13年。菲利普斯先生此前还曾担任多个学术组织的董事会成员，例如佩珀代因大学董事会和阿比林基督教大学投资委员会。Phillips先生曾在AdvancePCS担任多个与财务相关的职务超过11年，包括担任其首席财务官和高级执行副总裁，直到2004年AdvancePCS与CVS Caremark Corporation合并。在加入AdvancePCS之前，菲利普斯先生曾在德克萨斯州从事碳氢化合物勘探的公司Harken Energy Corporation（现为HKN Inc.）和夏威夷的汽油营销商和便利店运营商Aloha Petroleum，Ltd.担任过多个高级财务职务。菲利普斯先生拥有阿比林基督教大学会计学文学学士学位。
Danny Phillips,has served as a member of the company's board of directors since August 2015. Mr. Phillips is currently the owner of the Diamond P Longhorn Ranch in Lindale, Texas, and manages his own financial investments. Mr. Phillips currently serves as a member of the board of directors of Fortress Youth Development Center, a non-profit organization that aids the homeless community and low-income families in Fort Worth, Texas, and served as its Chairperson from 2007 to 2015. In addition, Mr. Phillips currently serves as a member of the board of directors of Mission Increase Fort Worth, a non-profit organization that offers teaching, coaching, consulting, and fundraising tools to help other non-profits grow and be successful. He also previously served as a member of the board of directors of Texas Mutual Insurance Company, a workers' compensation provider in Texas, a position he held for thirteen years. Mr. Phillips has also previously served as a member of the board of directors of various academic organizations, such as on the board of regents at Pepperdine University and the investment board of Abilene Christian University. Mr. Phillips served in various finance-related roles at AdvancePCS for over 11 years, including as its Chief Financial Officer and Senior Executive Vice President until its merger with CVS Caremark Corporation in 2004. Prior to AdvancePCS, Mr. Phillips served various senior financial roles at Harken Energy Corporation (now HKN Inc.), a company engaged in hydrocarbon exploration in Texas, and Aloha Petroleum, Ltd., a gasoline marketer and convenience store operator in Hawaii. Mr. Phillips holds a Bachelor of Arts in Accounting from Abilene Christian University. - Danny Phillips，自2015年8月起担任公司董事会成员。菲利普斯先生目前是德克萨斯州林代尔钻石P长角牛牧场的所有者，并管理自己的金融投资。菲利普斯先生目前担任Fortress Youth Development Center的董事会成员，该中心是一家帮助德克萨斯州沃思堡无家可归者社区和低收入家庭的非营利组织，并在2007年至2015年期间担任其主席。此外，菲利普斯先生目前担任Mission Increase Fort Worth的董事会成员，这是一家非营利组织，提供教学、辅导、咨询和筹款工具，以帮助其他非营利组织成长并取得成功。此前，他还曾担任得州工人补偿提供商Texas Mutual Insurance Company的董事会成员，该职位他担任了13年。菲利普斯先生此前还曾担任多个学术组织的董事会成员，例如佩珀代因大学董事会和阿比林基督教大学投资委员会。Phillips先生曾在AdvancePCS担任多个与财务相关的职务超过11年，包括担任其首席财务官和高级执行副总裁，直到2004年AdvancePCS与CVS Caremark Corporation合并。在加入AdvancePCS之前，菲利普斯先生曾在德克萨斯州从事碳氢化合物勘探的公司Harken Energy Corporation（现为HKN Inc.）和夏威夷的汽油营销商和便利店运营商Aloha Petroleum，Ltd.担任过多个高级财务职务。菲利普斯先生拥有阿比林基督教大学会计学文学学士学位。
- Danny Phillips,has served as a member of the company's board of directors since August 2015. Mr. Phillips is currently the owner of the Diamond P Longhorn Ranch in Lindale, Texas, and manages his own financial investments. Mr. Phillips currently serves as a member of the board of directors of Fortress Youth Development Center, a non-profit organization that aids the homeless community and low-income families in Fort Worth, Texas, and served as its Chairperson from 2007 to 2015. In addition, Mr. Phillips currently serves as a member of the board of directors of Mission Increase Fort Worth, a non-profit organization that offers teaching, coaching, consulting, and fundraising tools to help other non-profits grow and be successful. He also previously served as a member of the board of directors of Texas Mutual Insurance Company, a workers' compensation provider in Texas, a position he held for thirteen years. Mr. Phillips has also previously served as a member of the board of directors of various academic organizations, such as on the board of regents at Pepperdine University and the investment board of Abilene Christian University. Mr. Phillips served in various finance-related roles at AdvancePCS for over 11 years, including as its Chief Financial Officer and Senior Executive Vice President until its merger with CVS Caremark Corporation in 2004. Prior to AdvancePCS, Mr. Phillips served various senior financial roles at Harken Energy Corporation (now HKN Inc.), a company engaged in hydrocarbon exploration in Texas, and Aloha Petroleum, Ltd., a gasoline marketer and convenience store operator in Hawaii. Mr. Phillips holds a Bachelor of Arts in Accounting from Abilene Christian University.
- Jeffrey Vacirca
-
Jeffrey Vacirca，自2024年11月起担任公司董事会成员。自2008年以来，Vacirca博士一直担任纽约癌症和血液专家委员会的首席执行官和主席，这是一家专门从事血液学/肿瘤学和医学肿瘤学的癌症护理中心。自2011年起，他担任国家转化研究集团的总裁和联合创始人，该集团专注于非临床研究。2012年至2023年，他在医药产品公司Amerisource Bergen担任国际肿瘤网络专科组的医学总监和战略顾问。自2018年以来，Vacirca博士担任西奈山健康网络肿瘤网络发展的医学主任，并担任纽约西奈山伊坎医学院的临床副教授。他曾于2008年至2024年担任长岛艾滋病护理协会的医疗主任。Vacirca博士还在私营公司Annexus Health、OneOncology（他曾是该公司的联合创始人）和PatientPoint的董事会任职。Vacirca博士于2023年7月至2024年11月期间担任上市药企Assertio Holdings的董事，上市药企光谱制药于2018年11月至2023年7月期间担任Assertio的收购案，以及于2020年12月至2022年4月期间担任上市生物制药公司BeyondSpring Inc.的董事。Vacirca博士是社区肿瘤学联盟的前任主席，并继续担任其执行委员会的成员。他还参与了Cedar、Thyme Care和Sherpa Health等多家公司的早期融资。Vacirca博士于2016年与他人共同创立了一家上市制药公司Odonate治疗，并担任董事至2019年9月。Vacirca博士是纽约癌症基金会的创始人和董事会主席，该基金会为接受癌症治疗的患者提供经济援助。Vacirca博士拥有奥尔巴尼大学人类生物学文学学士学位和圣乔治大学医学博士学位。
Jeffrey Vacirca,has served as a member of the company's board of directors since November 2024. Since 2008, Dr. Vacirca has served as Chief Executive Officer and Chairman of the Board of New York Cancer & Blood Specialists, a cancer care center specializing in hematology/oncology and medical oncology. Since 2011, he has served as President and Co-Founder of National Translational Research Group, a group focusing on non-clinical research, and, from 2012 to 2023, he served as a Medical Director and Strategic Advisor for the International Oncology Network specialty group at Amerisource Bergen, a pharmaceutical products company. Since 2018, Dr. Vacirca has served as the Medical Director of the Oncology Network Development at Mount Sinai Health Network and as an associate clinical professor at Icahn School of Medicine at Mount Sinai, New York. He served as Medical Director for the Long Island Association for AIDS Care from 2008 to 2024. Dr. Vacirca also serves on the boards of directors of privately held companies Annexus Health, OneOncology (where he was a co-founder) and PatientPoint. Dr. Vacirca served as a director of Assertio Holdings, a publicly-traded pharmaceutical company, from July 2023 to November 2024, Spectrum Pharmaceuticals, a publicly-traded pharmaceutical company, from November 2018 to its July 2023 acquisition by Assertio, and BeyondSpring Inc., a publicly traded biopharmaceutical company, from December 2020 to April 2022. Dr. Vacirca is the past president of the Community Oncology Alliance and continues to be a member of its executive committee. He has also been part of early funding for various companies including Cedar, Thyme Care, and Sherpa Health. Dr. Vacirca co-founded Odonate Therapeutics, a publicly held pharmaceutical company, in 2016 and served as a director until September 2019. Dr. Vacirca is the founder and Chairman of the Board of Directors of the New York Cancer Foundation, which provides financial assistance to patients undergoing treatment for cancer. Dr. Vacirca holds a Bachelor of Arts in Human Biology from the University at Albany and a Doctor of Medicine from St. George's University. - Jeffrey Vacirca，自2024年11月起担任公司董事会成员。自2008年以来，Vacirca博士一直担任纽约癌症和血液专家委员会的首席执行官和主席，这是一家专门从事血液学/肿瘤学和医学肿瘤学的癌症护理中心。自2011年起，他担任国家转化研究集团的总裁和联合创始人，该集团专注于非临床研究。2012年至2023年，他在医药产品公司Amerisource Bergen担任国际肿瘤网络专科组的医学总监和战略顾问。自2018年以来，Vacirca博士担任西奈山健康网络肿瘤网络发展的医学主任，并担任纽约西奈山伊坎医学院的临床副教授。他曾于2008年至2024年担任长岛艾滋病护理协会的医疗主任。Vacirca博士还在私营公司Annexus Health、OneOncology（他曾是该公司的联合创始人）和PatientPoint的董事会任职。Vacirca博士于2023年7月至2024年11月期间担任上市药企Assertio Holdings的董事，上市药企光谱制药于2018年11月至2023年7月期间担任Assertio的收购案，以及于2020年12月至2022年4月期间担任上市生物制药公司BeyondSpring Inc.的董事。Vacirca博士是社区肿瘤学联盟的前任主席，并继续担任其执行委员会的成员。他还参与了Cedar、Thyme Care和Sherpa Health等多家公司的早期融资。Vacirca博士于2016年与他人共同创立了一家上市制药公司Odonate治疗，并担任董事至2019年9月。Vacirca博士是纽约癌症基金会的创始人和董事会主席，该基金会为接受癌症治疗的患者提供经济援助。Vacirca博士拥有奥尔巴尼大学人类生物学文学学士学位和圣乔治大学医学博士学位。
- Jeffrey Vacirca,has served as a member of the company's board of directors since November 2024. Since 2008, Dr. Vacirca has served as Chief Executive Officer and Chairman of the Board of New York Cancer & Blood Specialists, a cancer care center specializing in hematology/oncology and medical oncology. Since 2011, he has served as President and Co-Founder of National Translational Research Group, a group focusing on non-clinical research, and, from 2012 to 2023, he served as a Medical Director and Strategic Advisor for the International Oncology Network specialty group at Amerisource Bergen, a pharmaceutical products company. Since 2018, Dr. Vacirca has served as the Medical Director of the Oncology Network Development at Mount Sinai Health Network and as an associate clinical professor at Icahn School of Medicine at Mount Sinai, New York. He served as Medical Director for the Long Island Association for AIDS Care from 2008 to 2024. Dr. Vacirca also serves on the boards of directors of privately held companies Annexus Health, OneOncology (where he was a co-founder) and PatientPoint. Dr. Vacirca served as a director of Assertio Holdings, a publicly-traded pharmaceutical company, from July 2023 to November 2024, Spectrum Pharmaceuticals, a publicly-traded pharmaceutical company, from November 2018 to its July 2023 acquisition by Assertio, and BeyondSpring Inc., a publicly traded biopharmaceutical company, from December 2020 to April 2022. Dr. Vacirca is the past president of the Community Oncology Alliance and continues to be a member of its executive committee. He has also been part of early funding for various companies including Cedar, Thyme Care, and Sherpa Health. Dr. Vacirca co-founded Odonate Therapeutics, a publicly held pharmaceutical company, in 2016 and served as a director until September 2019. Dr. Vacirca is the founder and Chairman of the Board of Directors of the New York Cancer Foundation, which provides financial assistance to patients undergoing treatment for cancer. Dr. Vacirca holds a Bachelor of Arts in Human Biology from the University at Albany and a Doctor of Medicine from St. George's University.
高管简历
中英对照 | 中文 | 英文- David D. Halbert
David D. Halbert，2008年创立Caris Life Sciences，Inc.，自Caris Life Sciences，Inc.成立以来一直担任Caris Life Sciences，Inc.首席执行官和Caris Life Sciences，Inc.董事会主席。哈尔伯特先生和他的家人还创建并单独支持Caris基金会，这是一个成立于2002年的非营利性私人基金会，通过帮助满足贫困人口的基本需求来帮助他们。从2005年到2011年，Halbert先生担任Caris Diagnostics的董事长兼首席执行官，Caris Diagnostics是一家总部位于德克萨斯州的专门从事胃肠道病理的病理学公司，该公司于2011年被出售给Miraca Life Sciences。在加入Caris Diagnostics之前，Halbert先生曾担任AdvancePCS Inc.（“AdvancePCS”）的董事长兼首席执行官，该公司是他于1987年创立的处方福利计划管理人。Halbert先生拥有阿比林基督教大学工商管理学士学位和阿比林基督教大学荣誉理学博士学位，以表彰他对精准医学的贡献和他的全球慈善工作。
David D. Halbert,and his family also created and solely support the Caris Foundation, a non-profit, private foundation formed in 2002 that aids impoverished people by helping to provide for their basic needs. From 2005 to 2011, Mr. Halbert served as Chairman and Chief Executive Officer of Caris Diagnostics, a Texas-based pathology company specializing in gastrointestinal pathology, which was sold to Miraca Life Sciences in 2011. Prior to Caris Diagnostics, Mr. Halbert served as Chairman and Chief Executive Officer of AdvancePCS Inc. ("AdvancePCS"), a prescription benefit plan administrator that he founded in 1987. Mr. Halbert holds a Bachelor of Business Administration from Abilene Christian University and an honorary Doctor of Science from Abilene Christian University for his contributions to precision medicine and his global philanthropic work.- David D. Halbert，2008年创立Caris Life Sciences，Inc.，自Caris Life Sciences，Inc.成立以来一直担任Caris Life Sciences，Inc.首席执行官和Caris Life Sciences，Inc.董事会主席。哈尔伯特先生和他的家人还创建并单独支持Caris基金会，这是一个成立于2002年的非营利性私人基金会，通过帮助满足贫困人口的基本需求来帮助他们。从2005年到2011年，Halbert先生担任Caris Diagnostics的董事长兼首席执行官，Caris Diagnostics是一家总部位于德克萨斯州的专门从事胃肠道病理的病理学公司，该公司于2011年被出售给Miraca Life Sciences。在加入Caris Diagnostics之前，Halbert先生曾担任AdvancePCS Inc.（“AdvancePCS”）的董事长兼首席执行官，该公司是他于1987年创立的处方福利计划管理人。Halbert先生拥有阿比林基督教大学工商管理学士学位和阿比林基督教大学荣誉理学博士学位，以表彰他对精准医学的贡献和他的全球慈善工作。
- David D. Halbert,and his family also created and solely support the Caris Foundation, a non-profit, private foundation formed in 2002 that aids impoverished people by helping to provide for their basic needs. From 2005 to 2011, Mr. Halbert served as Chairman and Chief Executive Officer of Caris Diagnostics, a Texas-based pathology company specializing in gastrointestinal pathology, which was sold to Miraca Life Sciences in 2011. Prior to Caris Diagnostics, Mr. Halbert served as Chairman and Chief Executive Officer of AdvancePCS Inc. ("AdvancePCS"), a prescription benefit plan administrator that he founded in 1987. Mr. Halbert holds a Bachelor of Business Administration from Abilene Christian University and an honorary Doctor of Science from Abilene Christian University for his contributions to precision medicine and his global philanthropic work.
- Brian J. Brille
Brian J. Brille，自2018年1月起担任Caris Life Sciences，Inc.副董事长兼执行副总裁，并担任Caris Life Sciences，Inc.董事会成员。布里尔先生目前担任癌症研究所董事会成员，该研究所是一家资助癌症研究的非营利组织。自2022年以来，Brille先生还担任国际生物医学Research Alliance的董事会成员，这是一个非营利组织，其使命是支持NIH牛津-剑桥学者计划。在加入Caris之前，Brille先生曾于1999年至2013年在跨国投资银行和金融服务公司美银美林（现为BoFA Securities，Inc.）担任多个与金融相关的职务，包括最近于2009年至2013年担任亚太区主席兼总裁，于2005年至2008年担任企业和投资银行业务主管，并于1999年至2004年担任医疗保健投资银行业务主管。Brille先生的职业生涯始于1987年的跨国投资银行和金融服务公司摩根士丹利 & Co. LLC（“摩根士丹利”），并创立了摩根士丹利的医疗保健服务投资银行集团。布里尔先生拥有斯坦福大学法学院法学博士学位、哈佛大学肯尼迪学院公共政策硕士学位以及伊利诺伊大学会计学学士学位。
Brian J. Brille has served as Vice Chairman and Executive Vice President and as a member of board of directors since January 2018. Mr. Brille currently serves as a member of the board of trtees at the Cancer Research Institute, a non profit organization funding cancer research. Since 2022, Mr. Brille has also served as a member of the board of directors at the International Biomedical Research Alliance, a nonprofit organization with a mission to support the NIH Oxford Cambridge Scholars Program. Prior to joining Caris, Mr. Brille served in vario finance related roles for Bank of America Merrill Lynch (now BofA Securities, Inc.), a multinational investment bank and financial services company, from 1999 to 2013, including most recently as Chairman and President of Asia Pacific from 2009 to 2013, as Head of Corporate and Investment Banking from 2005 to 2008, and as Head of Healthcare Investment Banking from 1999 to 2004. Mr. Brille began his career in 1987 at Morgan Stanley & Co. LLC ("Morgan Stanley"), a multinational investment bank and financial services company, and founded Morgan Stanley's Healthcare Services Investment Banking Group. Mr. Brille holds a Juris Doctor from Stanford Law School, a Master in Public Policy from the Harvard Kennedy School, and a Bachelor of Science in Accounting from the University of Illinois.- Brian J. Brille，自2018年1月起担任Caris Life Sciences，Inc.副董事长兼执行副总裁，并担任Caris Life Sciences，Inc.董事会成员。布里尔先生目前担任癌症研究所董事会成员，该研究所是一家资助癌症研究的非营利组织。自2022年以来，Brille先生还担任国际生物医学Research Alliance的董事会成员，这是一个非营利组织，其使命是支持NIH牛津-剑桥学者计划。在加入Caris之前，Brille先生曾于1999年至2013年在跨国投资银行和金融服务公司美银美林（现为BoFA Securities，Inc.）担任多个与金融相关的职务，包括最近于2009年至2013年担任亚太区主席兼总裁，于2005年至2008年担任企业和投资银行业务主管，并于1999年至2004年担任医疗保健投资银行业务主管。Brille先生的职业生涯始于1987年的跨国投资银行和金融服务公司摩根士丹利 & Co. LLC（“摩根士丹利”），并创立了摩根士丹利的医疗保健服务投资银行集团。布里尔先生拥有斯坦福大学法学院法学博士学位、哈佛大学肯尼迪学院公共政策硕士学位以及伊利诺伊大学会计学学士学位。
- Brian J. Brille has served as Vice Chairman and Executive Vice President and as a member of board of directors since January 2018. Mr. Brille currently serves as a member of the board of trtees at the Cancer Research Institute, a non profit organization funding cancer research. Since 2022, Mr. Brille has also served as a member of the board of directors at the International Biomedical Research Alliance, a nonprofit organization with a mission to support the NIH Oxford Cambridge Scholars Program. Prior to joining Caris, Mr. Brille served in vario finance related roles for Bank of America Merrill Lynch (now BofA Securities, Inc.), a multinational investment bank and financial services company, from 1999 to 2013, including most recently as Chairman and President of Asia Pacific from 2009 to 2013, as Head of Corporate and Investment Banking from 2005 to 2008, and as Head of Healthcare Investment Banking from 1999 to 2004. Mr. Brille began his career in 1987 at Morgan Stanley & Co. LLC ("Morgan Stanley"), a multinational investment bank and financial services company, and founded Morgan Stanley's Healthcare Services Investment Banking Group. Mr. Brille holds a Juris Doctor from Stanford Law School, a Master in Public Policy from the Harvard Kennedy School, and a Bachelor of Science in Accounting from the University of Illinois.
- David Spetzler
David Spetzler，自2016年11月起担任Caris Life Sciences，Inc.总裁。自2007年以来，斯佩茨勒博士还担任亚利桑那州立大学分子细胞生物学项目的兼职教员。Spetzler博士于2009年8月加入Caris，担任高级科学家，并在任职期间担任过各种资历不断增加的角色。在Caris之前，Spetzler博士曾于2003年1月至2009年8月在亚利桑那州立大学担任多个研究教师职务。Spetzler博士拥有亚利桑那州立大学理学硕士、分子与细胞生物学哲学博士、工商管理硕士学位。
David Spetzler has served as President since November 2016. Dr. Spetzler has also served as an adjunct faculty member of the molecular and cellular biology program at Arizona State University since 2007. Dr. Spetzler joined Caris in Augt 2009 as a Senior Scientist and has served in a variety of roles of increasing seniority during his tenure. Before Caris, Dr. Spetzler served in vario research faculty roles at Arizona State University from January 2003 to Augt 2009. Dr. Spetzler holds a Master of Science, a Doctor of Philosophy in Molecular & Cellular Biology, and a Master of Biness Administration from Arizona State University.- David Spetzler，自2016年11月起担任Caris Life Sciences，Inc.总裁。自2007年以来，斯佩茨勒博士还担任亚利桑那州立大学分子细胞生物学项目的兼职教员。Spetzler博士于2009年8月加入Caris，担任高级科学家，并在任职期间担任过各种资历不断增加的角色。在Caris之前，Spetzler博士曾于2003年1月至2009年8月在亚利桑那州立大学担任多个研究教师职务。Spetzler博士拥有亚利桑那州立大学理学硕士、分子与细胞生物学哲学博士、工商管理硕士学位。
- David Spetzler has served as President since November 2016. Dr. Spetzler has also served as an adjunct faculty member of the molecular and cellular biology program at Arizona State University since 2007. Dr. Spetzler joined Caris in Augt 2009 as a Senior Scientist and has served in a variety of roles of increasing seniority during his tenure. Before Caris, Dr. Spetzler served in vario research faculty roles at Arizona State University from January 2003 to Augt 2009. Dr. Spetzler holds a Master of Science, a Doctor of Philosophy in Molecular & Cellular Biology, and a Master of Biness Administration from Arizona State University.
- Luke Power
路克动力，自2023年2月起担任Caris Life Sciences，Inc.高级副总裁、首席财务官、首席会计官。Power先生于2011年12月加入Caris，担任财务报告和会计经理，并在任职期间担任过多种资历递增的职务，包括2017年4月至2023年2月担任首席会计官,2016年5月至2016年9月担任会计部高级总监，2013年8月至2016年5月担任会计部总监。在加入Caris之前，Power先生于2002年11月至2011年10月在商业咨询服务提供商PricewaterhouseCoopers LLP担任国际鉴证业务经理。Power先生是一名注册会计师，也是爱尔兰特许会计师协会的资深会员。Power先生拥有爱尔兰沃特福德理工学院的金融和会计学位。
Luke Power has served as Senior Vice President, Chief Financial Officer, and Chief Accounting Officer since February 2023. Mr. Por joined Caris in December 2011 as a Financial Reporting and Accounting Manager and has served in a variety of roles of increasing seniority during his tenure, including as Chief Accounting Officer from April 2017 to February 2023, Senior Director of Accounting from May 2016 to September 2016, and Director of Accounting from August 2013 to May 2016. Prior to joining Caris, Mr. Por worked as a Manager in the international assurance practice at PricewaterhoeCoopers LLP, a provider of biness advisory services, from November 2002 to October 2011. Mr. Por is a certified public accountant and a Fellow of Chartered Accountants Ireland. Mr. Por holds a degree in finance and accounting from Waterford Institute of Technology in Ireland.- 路克动力，自2023年2月起担任Caris Life Sciences，Inc.高级副总裁、首席财务官、首席会计官。Power先生于2011年12月加入Caris，担任财务报告和会计经理，并在任职期间担任过多种资历递增的职务，包括2017年4月至2023年2月担任首席会计官,2016年5月至2016年9月担任会计部高级总监，2013年8月至2016年5月担任会计部总监。在加入Caris之前，Power先生于2002年11月至2011年10月在商业咨询服务提供商PricewaterhouseCoopers LLP担任国际鉴证业务经理。Power先生是一名注册会计师，也是爱尔兰特许会计师协会的资深会员。Power先生拥有爱尔兰沃特福德理工学院的金融和会计学位。
- Luke Power has served as Senior Vice President, Chief Financial Officer, and Chief Accounting Officer since February 2023. Mr. Por joined Caris in December 2011 as a Financial Reporting and Accounting Manager and has served in a variety of roles of increasing seniority during his tenure, including as Chief Accounting Officer from April 2017 to February 2023, Senior Director of Accounting from May 2016 to September 2016, and Director of Accounting from August 2013 to May 2016. Prior to joining Caris, Mr. Por worked as a Manager in the international assurance practice at PricewaterhoeCoopers LLP, a provider of biness advisory services, from November 2002 to October 2011. Mr. Por is a certified public accountant and a Fellow of Chartered Accountants Ireland. Mr. Por holds a degree in finance and accounting from Waterford Institute of Technology in Ireland.
- J. Russel Denton
J. Russell Denton，自2022年9月起担任Caris Life Sciences，Inc.高级副总裁、总法律顾问、秘书。在加入Caris之前，Denton先生曾担任国际律师事务所Shearman & Sterling LLP的合伙人，在2018年3月至2022年9月期间代表客户参与并购和股权融资交易。在加入Shearman & Sterling LLP之前，Denton先生曾于2012年5月至2018年2月担任Andrews Kurth Kenyon LLP的合伙人。丹顿先生的职业生涯始于2008年9月，当时他在Skadden，Arps，Slate，Meagher和Flom LLP担任合伙人。丹顿先生拥有斯坦福大学法学院的法学博士学位和杜克大学的理学学士学位。
J. Russel Denton has served as Senior Vice President, General Counsel, and Secretary since September 2022. Prior to joining Caris, Mr. Denton served as a partner at Shearman & Sterling LLP, an international law firm, representing clients in mergers and acquisitions and equity financing transactions from March 2018 to September 2022. Prior to Shearman & Sterling LLP, Mr. Denton served as a partner at Andrews Kurth Kenyon LLP from May 2012 to February 2018. Mr. Denton began his career in September 2008 as an associate at Skadden, Arps, Slate, Meagher and Flom LLP. Mr. Denton holds a Juris Doctor from Stanford Law School and a Bachelor of Science from Duke University.- J. Russell Denton，自2022年9月起担任Caris Life Sciences，Inc.高级副总裁、总法律顾问、秘书。在加入Caris之前，Denton先生曾担任国际律师事务所Shearman & Sterling LLP的合伙人，在2018年3月至2022年9月期间代表客户参与并购和股权融资交易。在加入Shearman & Sterling LLP之前，Denton先生曾于2012年5月至2018年2月担任Andrews Kurth Kenyon LLP的合伙人。丹顿先生的职业生涯始于2008年9月，当时他在Skadden，Arps，Slate，Meagher和Flom LLP担任合伙人。丹顿先生拥有斯坦福大学法学院的法学博士学位和杜克大学的理学学士学位。
- J. Russel Denton has served as Senior Vice President, General Counsel, and Secretary since September 2022. Prior to joining Caris, Mr. Denton served as a partner at Shearman & Sterling LLP, an international law firm, representing clients in mergers and acquisitions and equity financing transactions from March 2018 to September 2022. Prior to Shearman & Sterling LLP, Mr. Denton served as a partner at Andrews Kurth Kenyon LLP from May 2012 to February 2018. Mr. Denton began his career in September 2008 as an associate at Skadden, Arps, Slate, Meagher and Flom LLP. Mr. Denton holds a Juris Doctor from Stanford Law School and a Bachelor of Science from Duke University.